Pharmaceutical

Dalfampridine IR by Solaxa for Spinocerebellar Ataxia (SCA): Likelihood of Approval

Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA).

Jul 6, 2024 - 04:00
Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA).
Read the original article

Tags:

Previous Article

LP-184 by Starlight Therapeutics for Non-Small Cell Lung Cancer: Likelihood of A...

Next Article

AZD-2389 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MA...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: FDA advisers vote overwhelmingly against ALS treatment; weight-loss drugs scrutinized over reports of suicidal thoughts

STAT+: Pharmalittle: FDA advisers vote overwhelmingly a...

Sep 28, 2023

STAT+: What do new weight loss drugs mean for the future of bariatric surgery?

STAT+: What do new weight loss drugs mean for the futur...

Aug 29, 2023

Signal: Fresh Tracks nears end of operations with plans for dissolution

Signal: Fresh Tracks nears end of operations with plans...

Sep 21, 2023